Physician profile
Mary Bertossi
NPI 1649630310
$20,307.47
in general payments reported to CMS, 2019-2025
47 companies · $8,311 in 2025
The $8,311 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,965 · 2022: $1,768 · 2023: $2,460 · 2024: $1,804 · 2025: $8,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,949 · Consulting Fee: $4,210 · Travel and Lodging: $1,775 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,949.00 |
| Consulting Fee | $4,210.25 |
| Travel and Lodging | $1,775.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $640.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $6,372.27 | 2023-2025 | Fensolvi |
| Novo Nordisk As | $4,655.00 | 2021-2023 | Norditropin |
| Novo Nordisk INC | $1,264.46 | 2021-2025 | Sogroya, Wegovy, Norditropin |
| Pfizer INC. | $973.50 | 2021-2025 | |
| Abbvie INC. | $950.43 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $705.78 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $600.48 | 2023-2025 | |
| Sequel Med Tech, LLC | $419.23 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $375.73 | 2023-2025 | Triptodur, Triptodur, Adthyza |
| Amneal Pharmaceuticals LLC | $313.42 | 2021-2025 | Unithroid |
| Insulet Corporation | $302.15 | 2021-2024 | Omnipod |
| Zealand Pharma US, INC. | $271.04 | 2021-2022 | |
| Eton Pharmaceuticals, INC. | $253.01 | 2021-2025 | Alkindi, Khindivi, Increlex |
| Lilly USA, LLC | $239.44 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $199.38 | 2021-2025 | Minimed 780g |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $184.36 | 2021-2023 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $172.18 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $160.33 | 2024-2025 | Skytrofa |
| Beta Bionics, INC. | $140.62 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alexion Pharmaceuticals, INC. | $140.09 | 2021-2024 | Strensiq |
| Neurocrine Biosciences, INC. | $133.64 | 2024-2025 | |
| Mannkind Corporation | $129.52 | 2021-2025 | |
| Amphastar Pharmaceuticals, INC. | $125.71 | 2024-2025 | |
| Amryt Pharma Holdings LTD | $125.56 | 2021 | |
| Embecta Corp. | $121.55 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Endo Pharmaceuticals INC. | $117.43 | 2021-2023 | Supprelin |
| Kyowa Kirin, INC. | $105.23 | 2023-2025 | Crysvita |
| Abbott Laboratories | $87.68 | 2021-2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $69.76 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $65.18 | 2021-2025 | Voxzogo 1.2mg |
| Corcept Therapeutics | $60.28 | 2022-2024 | Korlym |
| Endo USA, INC. | $51.68 | 2024-2025 | Supprelin |
| Soleno Therapeutics, INC. | $47.59 | 2025 | Vykat Xr |
| Arbor Pharmaceuticals, INC. | $42.81 | 2021 | |
| Averitas Pharma INC. | $40.91 | 2023-2024 | Qutenza |
| Ibsa Pharma INC. | $37.91 | 2022-2024 | Tirosint, Licart |
| Rhythm Pharmaceuticals, INC. | $32.93 | 2025 | Imcivree |
| Amgen INC. | $30.00 | 2024 | Evenity |
| Madrigal Pharmaceuticals | $28.80 | 2024 | Resmetirom |
| Becton, Dickinson and Company | $25.57 | 2022 | |
| Sandoz INC. | $23.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.08 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $19.58 | 2022 | |
| Chiesi USA, INC. | $19.58 | 2025 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2024 | Farxiga |
| Cequr Corporation | $17.88 | 2025 | Cequr Simplicity |
| Ionis Pharmaceuticals, INC. | $15.49 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bertossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.